Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
1K-L and S1J-K )
Ginsenoside Rh1 alleviates allergic rhinitis by mediating mitochondrial autophagy via activation of the AMPK/ULK1/FUNDC1 pathway
Continuous Glucose Monitoring in People at High Risk of Diabetes and Dysglycaemia: Transforming Early Risk Detection and Personalised Care Our latest review explores how continuous glucose monitoring (CGM) could transform early detection and personalised management of diabetes risk Key Highlights: CGM reveals subtle patterns of dysglycaemia in high-risk individuals, including those with pre-symptomatic type 1 diabetes with positive islet autoantibodies, pre-type 2 diabetes or other metabolic dysfunction associated with changes in body composition, metabolic dysfunction-associated steatotic liver disease, gestational diabetes mellitus, solid organ transplantation, steroid treatment CGM-derived data are not yet validated for diabetes diagnosis, and challenges remain including limited evidence, lack of consensus on abnormal CGM values in people without diabetes, and uncertainty about optimal follow-up and management
Long-Term Cardiovascular Considerations Questions about long-term BPC-157 use remain largely unanswered by current research
China Demand for GLP-1 receptor agonists in China is projected to rise at 7.1% CAGR through 2036
Patients with specific GLP1R variants may achieve appetite suppression at lower doses or may require consistent dosing to maintain steady-state benefits
